

CoNCERT Pharmaceuticals Inc.®

Concert Pharmaceuticals
Investor Relations Department
99 Hayden Avenue, Suite 500
Lexington, MA 02421
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: CNCE

Last Trade:	26.62
Trade Time:	4:00 PM ET Dec 15, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	8.48 - 27.35
Volume	N/A


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

At Concert Pharmaceuticals, we are pioneering our industry-leading expertise in deuterium chemistry to discover and develop innovative drug products that have impact for patients and address important medical needs. Our innovative approach has already resulted in multiple drug candidates that offer improved ways to target a broad range of disease areas, including autoimmune and inflammatory diseases and central nervous system (CNS) disorders. Each of these novel candidates was designed to be improved with our deuterium chemistry, and is based on an approved drug, an advanced clinical candidate or a previously studied, biologically active compound.

[\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Dec 18, 2017

[Concert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial Officer](#)

Dec 13, 2017

[Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index](#)

Nov 9, 2017

[Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update](#)

Nov 6, 2017

[Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial](#)

Nov 2, 2017

[Concert Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 9, 2017, and Participate at Upcoming Investor Conferences](#)

Upcoming Events [\[View all \]](#)

Mar 20–21, 2018

[Oppenheimer's 28th Annual Healthcare Conference](#)

Apr 8–10, 2018

[H.C. Wainwright Global Life Sciences Conference](#)

Financials [\[View all \]](#)

Apr 26, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 9, 2017

[Quarterly Report \(10-Q\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)

May 2, 2017

[Quarterly Report \(10-Q\)](#)